Isodictya

OGGI Equity's Portfolio company Valentis is awarded Blanket Purchase Agreement with FEMA

Retrieved on: 
Tuesday, November 1, 2022
Growth, International, Federal Emergency Management Agency, FEMA, BPA, Federation, View, Government, OGGI, Private, Multimedia, Tropical Storm Ian, Public, Bottled water, Isodictya

MILAN and MIAMI, Nov. 1, 2022 /PRNewswire/ --OGGI Equity is pleased to announce that its portfolio company, Valentis Group has been awarded a Blanket Purchase Agreement (BPA) with the Federal Emergency Management Agency (FEMA) to support its recovery efforts in the State of Florida in wake of Hurricane Ian.

Key Points: 
  • MILAN and MIAMI, Nov. 1, 2022 /PRNewswire/ --OGGI Equity is pleased to announce that its portfolio company, Valentis Group has been awarded a Blanket Purchase Agreement (BPA) with the Federal Emergency Management Agency (FEMA) to support its recovery efforts in the State of Florida in wake of Hurricane Ian.
  • The twelve-month agreement with FEMA is designed to provide armed security services at various disaster recovery centers and branch offices for FEMA throughout Florida.
  • The BPA is the largest award, to date, from the federal government to Valentis.
  • OGGI Comments: "We are delighted and congratulate the Valentis team on this significant contract.

Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors

Retrieved on: 
Tuesday, March 29, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Hambrecht & Quist, Therapy, Health, Cancer, University, Chase, Population, Operation Xcellerator, Multimedia, Board, BIO, Hambrecht, Columbia University, Henry Purcell, Biotechnology Innovation Organization, Industry, Director, Â, Cornell University Board of Trustees, Isodictya, Campaign for Better Health Care, Executive Committee, Oncology, Patient, Popular Executive Committee of Valencia, Medicine, Management, Merck

Shorla Oncology ('Shorla'), an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman.

Key Points: 
  • Shorla Oncology ('Shorla'), an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman.
  • As a preeminent leader in the biotech industry, Purcell brings significant experience that will help guide Shorla in bringing their novel oncology products to the U.S. market.
  • We are thrilled to welcome Dennis to Shorla, said Sharon Cunningham, Chief Executive Officer of Shorla Oncology.
  • It is an honor to be appointed as Chairman on the Board at Shorla Oncology, said Purcell.

OGGI EQUITY'S PORTFOLIO COMPANY, VALENTIS GROUP, ATTENDS ISC WEST CONVENTION WITH NETWORK BANKING PARTNERS

Retrieved on: 
Tuesday, March 29, 2022
OGGI, Growth, Multimedia, Conference, Risk management, Exposition, Software, Investment, Industry, Equity, International, Isodictya, ISC, Financial services

MILAN and MIAMI, March 29, 2022 /PRNewswire/ -- (OGGI, VALENTIS) Oggi Equity announces the participation of Valentis Group, at ISC West Convention taking place March 22-25 at the Venetian Expo in Las Vegas. The International Security Conference & Exposition – also known as ISC West – is the leading comprehensive & converged security trade event in the U.S. with national and global attendance.

Key Points: 
  • MILAN and MIAMI, March 29, 2022 /PRNewswire/ -- (OGGI, VALENTIS)Oggi Equity announces the participation of Valentis Group, at ISC West Convention taking placeMarch22-25at the Venetian Expo in Las Vegas.
  • The International Security Conference & Exposition also known as ISC West is the leading comprehensive & converged security trade event in the U.S. with national and global attendance.
  • As an accredited U.S. Government vendor in Security, Valentis Group represents a unique opportunity for these security service firms to be associated with a group of its stature.
  • Valentis is a fully operational security logistics and risk management solution for a variety of clients and security concerns.

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

Retrieved on: 
Monday, October 11, 2021
Company, National Kidney Foundation, Trustee, Therapy, Harvard Law School, Intuitive Surgical, Latham & Watkins, Isodictya, General counsel, Amgen, Latham, GLOBE, Industry, CHRS, Research, Board, Buck Institute for Research on Aging, Cadence Design Systems, University, QLT, Berkeley, Emerging, Ageing, CEO, Felix Mendelssohn, Association, Cooley, Mellanox Technologies, Cooley LLP, Management

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson.
  • I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors.
  • On behalf of the entire Coherus team and Board, I offer our deep and heartfelt condolences to the Mendelson family.
  • In addition to his service on the Coherus board, Mr. Mendelson was General Counsel and Secretary at Blade Therapeutics and a Director of Neuvogen, Inc.